Article Text
Abstract
Aims To investigate the clinicopathological features, immunophenotypes and differential diagnosis of CD5-positive splenic marginal zone lymphoma (SMZL).
Methods We retrospectively analysed 16 CD5-positive cases of SMZL. Assess their clinicopathological features and survival outcomes to evaluate their similarities and differences with a control group of 25 CD5-negative cases of SMZL.
Results Compared with CD5-negative patients, CD5-positive SMZL tends to be more prone to B symptoms, peripheral lymphadenopathy and extranodal infiltration, high Ann Arbor stage, high International Prognostic Index scores, high serum lactic dehydrogenase and high rates of bone marrow involvement. The 5-year survival rate was significantly shorter than that of the CD5-negative group (52.1% and 81.8%, respectively).
Conclusions There are many similarities between CD5-positive SMZL and classical CD5-negative SMZL in clinical presentations, morphology and immunohistochemistry, but the former may have a more aggressive clinical course with a poorer prognosis.
- LYMPHOMA
- IMMUNOPHENOTYPING
- DIAGNOSIS
- IMMUNOHISTOCHEMISTRY
- SPLEEN
Data availability statement
All data relevant to the study are included in the article or uploaded as supplementary information.
Statistics from Altmetric.com
Data availability statement
All data relevant to the study are included in the article or uploaded as supplementary information.
Footnotes
Handling editor Vikram Deshpande.
WZ and WL contributed equally.
Contributors YL: responsible for the overall content as the guarantor, investigation, data curation, formal analysis and writing – original draft; GW: writing – review and editing; EL: writing – review and editing; DZ: resources; YZ: resources; XJ: resources; WZ and WL: conceptualisation, supervision and funding acquisition.
Funding This work was supported by the National Natural Science Foundation of China (Grant No. 82170184).
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.